|
|
rhIL-7 adjuvant |
|
Vaxjo ID |
376 |
|
Vaccine Adjuvant Name |
rhIL-7 adjuvant |
|
Adjuvant VO ID |
VO_0005532
|
|
Description |
cytokine adjuvant |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Second Host Species for Testing |
Mouse |
|
Components |
recombinant human IL-7 (rhIL-7) |
|
Preparation |
lyophilized, reconstituted with sterile water, and resuspended in buffer containing 5% sucrose and 0.1% HSA in PBS |
|
Dosage |
3, 10, 30 and 60 μg / Kg per dose |
|
Function |
Supports long-term immune memory |
| References |
Lévy et al., 2012: Lévy Y, Sereti I, Tambussi G, Routy JP, Lelièvre JD, Delfraissy JF, Molina JM, Fischl M, Goujard C, Rodriguez B, Rouzioux C, Avettand-Fenoël V, Croughs T, Beq S, Morre M, Poulin JF, Sekaly RP, Thiebaut R, Lederman MM. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2012; 55(2); 291-300. [PubMed: 22550117].
Melchionda et al., 2005: Melchionda F, Fry TJ, Milliron MJ, McKirdy MA, Tagaya Y, Mackall CL. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. The Journal of clinical investigation. 2005; 115(5); 1177-1187. [PubMed: 15841203].
Sportès et al., 2010: Sportès C, Babb RR, Krumlauf MC, Hakim FT, Steinberg SM, Chow CK, Brown MR, Fleisher TA, Noel P, Maric I, Stetler-Stevenson M, Engel J, Buffet R, Morre M, Amato RJ, Pecora A, Mackall CL, Gress RE. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010; 16(2); 727-735. [PubMed: 20068111].
|
|
